Liquid biopsy offers quick and easy access to tumor samples, as well as the potential for serial sampling. This non-invasive technology makes it feasible to expand oncology research to include cohorts that are unable to undergo a standard biopsy procedure or did not yield adequate tissue samples. With liquid biopsy, researchers can analyze biomarkers circulating in the bloodstream obtained through a conventional blood draw.
Circulating tumor DNA (ctDNA) has gained significance as a biomarker for cancer as they are released into the bloodstream by delocalized tumor cells, thus having the potential to provide a more accurate representation of tumor heterogeneity compared to tissue samples.1
There is very little circulating DNA per blood draw2
A very small percentage (as few as 0.01%) of circulating DNA is tumor-derived3
Tumor-specific mutations differ among research subjects4
AVENIO ctDNA Analysis Kits, a portfolio of three next-generation sequencing (NGS) liquid biopsy assays, overcome these challenges with proven molecular techniques and proprietary error suppression strategies.5